Adriana Telles

Adriana Telles

Auto-generated profile, based on publicly available information

Adriana Telles

Centro de Oncologia, Hospital Sírio Libanês, Rua Dona Adma Jafet 91, São Paulo, 01308-050, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2012 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
RCRachel Jorge D Cossetti
Rachel Jorge D Cossetti
RBRegis Otaviano França Bezerra
Regis Otaviano França Bezerra
BGBrenda Gumz
Brenda Gumz
ATAdriana Telles
Adriana Telles
FCFrederico P Costa
Frederico P Costa
Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs.